Clinical trials: Multiple Sclerosis, completed
Multiple Sclerosis, Relapsing-Remitting
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
- Trial name
- NCT00030966
- Testing
- Natalizumab
- Where
- 88 sites in United States, Austria and 5 more
- Volunteers
- 1,200 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
The purpose of this study is to determine if natalizumab in combination with Glatiramer Acetate (GA) is safe and effective in delaying progression of individuals diagnosed with relapsing-remitting Multiple Sclerosis (MS).
- Trial name
- NCT00097760
- Testing
- Natalizumab
- Volunteers
- 110 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
GER-009-06-AVX Early Therapy in Multiple Sclerosis
This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.
- Trial name
- FIT (NCT00492570)
- Volunteers
- 230 people
- Sponsor
- Biogen
Multiple Sclerosis
Development and Evaluation of a New Palliative Care Service for People Severely Affected With Multiple Sclerosis (MS)
The primary purpose of this study is to develop, implement and conduct a preliminary evaluation of a new service for people who are severely affected by multiple sclerosis.
- Trial name
- NCT00364936
- Testing
- Palliative care service
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- King's College London
Multiple Sclerosis
Immunogenicity and Safety Study of Serum-Free Avonex
To evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis.
- Trial name
- NCT00912860
- Testing
- Interferon beta-1a
- Volunteers
- 155 people
- Sponsor
- Biogen
Multiple Sclerosis
Open-Label Safety Extension Study of Avonex
To collect data on serious adverse events which occur during extended treatment with Avonex in subjects at high risk for developing multiple sclerosis (MS) and in subjects with secondary progressive MS.
- Trial name
- NCT00915460
- Testing
- Interferon beta-1a (Avonex)
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis
Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
Determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled Avonex syringe.
- Trial name
- NCT00915577
- Testing
- Interferon beta-1a, Single-use autoinjector
- Volunteers
- 74 people
- Sponsor
- Biogen
Multiple Sclerosis
A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers
Demonstrate the bioequivalence of a serum-free solution to a serum containing solution of Avonex.
- Trial name
- NCT00913250
- Testing
- Serum containing Avonex, Serum Free Avonex
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis
Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
This study will look at differences in bioanalytical measures among different groups of MS patients and Healthy Volunteers, when administered interferon beta-1a.
- Trial name
- NCT00913666
- Testing
- Interferon beta-1a (Avonex)
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Biogen
Stroke, Brain Injury
Motor Imagery Practice in Neurological Rehabilitation
Motor imagery is a technique widely used in learning skills. Its effectiveness has been proven in various sports and in musicians. A recent review (Braun et al.
- Conditions
- Stroke, Brain Injury, Multiple Sclerosis
- Trial name
- NCT00618085
- Testing
- Motor imagery practice, Standard physiotherapy and occupational therapy
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Nuffield Orthopaedic Centre NHS Trust
Multiple Sclerosis, Relapsing Remitting
Differential Immune Effects of Natalizumab
Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS).
- Trial name
- NCT00859482
- Volunteers
- 27 people
- Sponsor
- Cantonal Hospital of St. Gallen
Muscle Spasticity
Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
Nightly administration of 8 mg of a unique sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve next-day spasticity, about 12 hours following…
- Trial name
- NCT00358293
- Testing
- Tizanidine (sublingual or oral)
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Teva GTC
Relapsing Remitting Multiple Sclerosis, Sleep Initiation and Maintenance Disorders
Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)
The purpose of this study is to determine if people with multiple sclerosis (MS) and fatigue have disrupted sleep, as was suggested in previous studies, and whether treating the disruptions of sleep improves the fatigue.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Sleep Initiation and Maintenance Disorders, Fatigue
- Trial name
- NCT00594087
- Testing
- eszopiclone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Vermont
Multiple Sclerosis, Relapsing-Remitting
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
The purpose of this study is to determine whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms whether…
- Trial name
- NCT00099502
- Testing
- Interferon beta-1b (Betaferon/Betaseron, BAY86-5046), Copaxone
- Where
- 199 sites in United States, Argentina and 24 more
- Volunteers
- 2,244 people
- Sponsor
- Bayer
Multiple Sclerosis
Whole Body Vibration Therapy in a Participant With Multiple Sclerosis Related Balance Deficits - A Case Study
The purpose of this investigation is to determine the effect of Whole Body Vibration Therapy (WBV) on balance in a participant with multiple sclerosis (MS) related balance deficits as measured by the NeuroCom Balance Master, the…
- Trial name
- NCT00343590
- Testing
- Whole Body Vibration machine
- Where
- 2 sites in United States
- Sponsor
- Logan College of Chiropractic
Multiple Sclerosis
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis
OBJECTIVES: I. Determine whether high-dose intravenous immune globulin (IVIG) is more effective than placebo in restoring neurologic function (muscle strength) in patients with multiple sclerosis. II.
- Trial name
- NCT00004744
- Testing
- immune globulin
- Volunteers
- 76 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis
Multiple Sclerosis and Heavy Progressive Resistance Training
The purpose of the present investigation is to determine whether MS patients can tolerate and benefit from heavy progressive resistance training.
- Trial name
- NCT00381576
- Testing
- Resistance training
- Where
- 2 sites in Denmark
- Volunteers
- 36 people
- Sponsor
- University of Aarhus
Multiple Sclerosis
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
This research study is being conducted in the U.S. and Europe to evaluate the safety and efficacy of daclizumab for the treatment of multiple sclerosis (MS).
- Trial name
- NCT00109161
- Testing
- Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
- Where
- 36 sites in United States, Canada
- Volunteers
- 270 people
- Sponsor
- PDL BioPharma, Inc.
Multiple Sclerosis
Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)
This trial will evaluate whether progressive multiple sclerosis associated with hemiparesis may benefit from Constraint-Induced Movement Therapy.
- Trial name
- NCT00695084
- Testing
- Constraint-Induced Movement Therapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Multiple Sclerosis Society
Multiple Sclerosis
Auditory Function in Patients With and Without Multiple Sclerosis
We propose to evaluate auditory function and neuropsychologic function in 150 Multiple Sclerosis (MS) patients and in 150 patients who do not have MS.
- Trial name
- NCT00037947
- Testing
- Hearing in Multiple Sclerosis
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- US Department of Veterans Affairs